KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Tax Provisions: 2016-2025

Historic Tax Provisions for Halozyme Therapeutics (HALO) over the last 10 years, with Sep 2025 value amounting to $43.7 million.

  • Halozyme Therapeutics' Tax Provisions rose 55.43% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.5 million, marking a year-over-year increase of 71.72%. This contributed to the annual value of $113.0 million for FY2024, which is 69.39% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Tax Provisions stood at $43.7 million for Q3 2025, which was up 9.88% from $39.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Tax Provisions ranged from a high of $43.7 million in Q3 2025 and a low of -$142.5 million during Q3 2021.
  • For the 3-year period, Halozyme Therapeutics' Tax Provisions averaged around $26.3 million, with its median value being $24.5 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Tax Provisions tumbled by 226,260.32% in 2021 and then skyrocketed by 12,531.03% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Tax Provisions (Quarterly) stood at -$12.0 million in 2021, then spiked by 209.44% to $13.1 million in 2022, then grew by 20.61% to $15.8 million in 2023, then skyrocketed by 160.99% to $41.2 million in 2024, then surged by 55.43% to $43.7 million in 2025.
  • Its Tax Provisions stands at $43.7 million for Q3 2025, versus $39.8 million for Q2 2025 and $25.7 million for Q1 2025.